Improving Health Equity in Cancer: A Community Grant Program

Improving Health Equity in Cancer: A Community Grant Program is a grant from Takeda Pharmaceutical Company Limited that funds community-based initiatives helping address the needs of medically underserved people with cancer through local patient advocacy organizations. The program reflects Takeda's commitment to improving cancer health equity, an area where advances in science have not equally benefited all patient populations.

Eligible entities must be local patient advocacy organizations directly serving people with cancer in local communities. Awards of up to $1,000,000 in competitive grant funds are distributed to multiple qualifying organizations. Applications are submitted during open application periods announced by Takeda.

Takeda Begins Accepting Applications for New Community Grant Program to Improve Cancer Health Equity Takeda Begins Accepting Applications for New Community Grant Program to Improve Cancer Health Equity Takeda Begins Accepting Applications for New Community Grant Program to Improve Cancer Health Equity # Takeda Begins Accepting Applications for New Community Grant Program to Improve Cancer Health Equity -- Up to $1 million in competitive grant funds will be distributed to multiple local patient advocacy organizations addressing needs of medically underserved people with cancer in their communities -- Cambridge, Mass.

,October 11, 2022 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the open application period for the Improving Health Equity in Cancer: A Community Grant Program . These competitive grants will make up to $1 million in funding available to multiple local patient advocacy organizations that help address the needs of medically underserved people with cancer through community-based initiatives.

“Takeda’s new community grant program represents our deep commitment to improving health equity in cancer – an area where advances in science have not benefited all patient populations equally,” Dion Warren, VP, Head of U.S. Oncology Business Unit at Takeda Pharmaceuticals. “We believe in the power of grassroots efforts to effect change.

We’re thrilled to be accepting applications from community-based organizations that share our vision to help people living with cancer improve health outcomes and achieve equitable healthcare. ” Eligible entities must be directly serving people with cancer in local communities.

Funding may be used to support ongoing or new initiatives that provide solutions for overcoming key barriers to achieving equitable health outcomes, including access, screening/testing and disease awareness. To apply for a competitive grant, visit the Takeda Support Portal . For more information about the Improving Health Equity in Cancer: A Community Grant Program, visit Improving Cancer Health Equity at the Local Level .

Takeda’s Commitment to Oncology Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.

takedaoncology. com. Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www. takeda. com .

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them.

These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda.

Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof.

These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.

takeda. com/investors/sec-filings/ or at www. sec.

gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

*-- Up to $1 million in competitive grant funds will be distributed to multiple local patient advocacy organizations addressing needs of medically underserved people with cancer in their communities --* **Cambridge, Mass. ,October 11, 2022** –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the open application period for the **Improving Health Equity in Cancer: A Community Grant Program**.

These competitive grants will make up to $1 million in funding available to multiple local patient advocacy organizations that help address the needs of medically underserved people with cancer through community-based initiatives.

“Takeda’s new community grant program represents our deep commitment to improving health equity in cancer – an area where advances in science have not benefited all patient populations equally,” Dion Warren, VP, Head of U.S. Oncology Business Unit at Takeda Pharmaceuticals. “We believe in the power of grassroots efforts to effect change.

We’re thrilled to be accepting applications from community-based organizations that share our vision to help people living with cancer improve health outcomes and achieve equitable healthcare. ” Eligible entities must be directly serving people with cancer in local communities.

Funding may be used to support ongoing or new initiatives that provide solutions for overcoming key barriers to achieving equitable health outcomes, including access, screening/testing and disease awareness. To apply for a competitive grant, visit the[ **Takeda Support Portal**](https://www. tsupportportal.

com/). For more information about the ***Improving Health Equity in Cancer: A Community Grant Program, visit ***[***Improving Cancer Health Equity at the Local Level***](https://www. takedaoncology.

com/news/our-viewpoints/improving-cancer-health-equity-at-the-local-level/)***. *** ## Takeda’s Commitment to Oncology Our core R\&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www. takedaoncology.

com. ## About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R\&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

Takeda focuses its R\&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R\&D investments in Plasma-Derived Therapies and Vaccines.

We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R\&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit **https://www. takeda. com**.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them.

These expressions are also used where no useful purpose is served by identifying the particular company or companies. ## Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda.

Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof.

These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: **https://www.

takeda. com/investors/sec-filings/ ** or at [**www. sec.

gov**](https://www. sec. gov/).

Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.